Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...
Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders ...
Linkage Global Inc. announced at the 2026 Consumer Electronics Show (CES) that it has entered strategic intellectual property partnerships with premium headphone brand ClickClack and VIBELENS. Under ...
Zacks Investment Research on MSN
Three genomics stocks worth tracking this year
An updated edition of the Nov. 18, 2025, article. Genomics is a broad and detailed study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Recent scientific advances in this ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
56m
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback